EGFR and glioblastoma: Thus, a vaccine called Rindopepimut, targeting the EGFR deletion mutation EGFRvIII, consisting of an EGFRvIII-specific peptide conjugated to keyhole limpet hemocyanin, was developed and tested in clinical trials for the treatment of EGFRvIII-positive glioblastomas [49].